GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immatics NV (NAS:IMTX) » Definitions » COGS-to-Revenue

Immatics NV (Immatics NV) COGS-to-Revenue : 0.00 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Immatics NV COGS-to-Revenue?

Immatics NV's Cost of Goods Sold for the three months ended in Mar. 2024 was $0.00 Mil. Its Revenue for the three months ended in Mar. 2024 was $32.90 Mil.

Immatics NV's COGS to Revenue for the three months ended in Mar. 2024 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Immatics NV's Gross Margin % for the three months ended in Mar. 2024 was N/A%.


Immatics NV COGS-to-Revenue Historical Data

The historical data trend for Immatics NV's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immatics NV COGS-to-Revenue Chart

Immatics NV Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
Get a 7-Day Free Trial - - - - -

Immatics NV Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Immatics NV COGS-to-Revenue Calculation

Immatics NV's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 58.884
=0.00

Immatics NV's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 32.901
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Immatics NV  (NAS:IMTX) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Immatics NV's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 0 / 32.901
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Immatics NV COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Immatics NV's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Immatics NV (Immatics NV) Business Description

Traded in Other Exchanges
Address
Paul-Ehrlich-Strasse 15, Tubingen, BW, DEU, 72076
Immatics NV is a biotechnology company that is engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.

Immatics NV (Immatics NV) Headlines

From GuruFocus